TNFRSF13B gene mutation in familial acute myeloid leukemia : A new piece in the complex scenario of hereditary predisposition?
© 2023 The Authors. Hematological Oncology published by John Wiley & Sons Ltd..
TNFRSF13B mutations are widely associated with common variable immunodeficiency. TNFRSF13B was recently counted among relevant genes associated with childhood-onset of hematological malignancies; nonetheless, its role in acute myeloid leukemia (AML) remains unexplored. We report the study of a family with two cases of AML, sharing a germline TNFRSF13B mutation favoring the formation of a more stable complex with its ligand TNFSF13: a positive regulator of AML-initiating cells. Our data turn the spotlight onto the TNFRSF13B role in AML onset, inserting a new fragment into the complex scenario of a hereditary predisposition to myeloid neoplasms.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:41 |
|---|---|
| Enthalten in: |
Hematological oncology - 41(2023), 5 vom: 21. Dez., Seite 942-946 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cumbo, Cosimo [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Case Reports |
|---|
| Anmerkungen: |
Date Completed 16.12.2023 Date Revised 16.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/hon.3212 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM360343783 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360343783 | ||
| 003 | DE-627 | ||
| 005 | 20231227132922.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/hon.3212 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1230.xml |
| 035 | |a (DE-627)NLM360343783 | ||
| 035 | |a (NLM)37534633 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cumbo, Cosimo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a TNFRSF13B gene mutation in familial acute myeloid leukemia |b A new piece in the complex scenario of hereditary predisposition? |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.12.2023 | ||
| 500 | |a Date Revised 16.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 The Authors. Hematological Oncology published by John Wiley & Sons Ltd. | ||
| 520 | |a TNFRSF13B mutations are widely associated with common variable immunodeficiency. TNFRSF13B was recently counted among relevant genes associated with childhood-onset of hematological malignancies; nonetheless, its role in acute myeloid leukemia (AML) remains unexplored. We report the study of a family with two cases of AML, sharing a germline TNFRSF13B mutation favoring the formation of a more stable complex with its ligand TNFSF13: a positive regulator of AML-initiating cells. Our data turn the spotlight onto the TNFRSF13B role in AML onset, inserting a new fragment into the complex scenario of a hereditary predisposition to myeloid neoplasms | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a TNFRSF13B | |
| 650 | 4 | |a familial AML | |
| 650 | 4 | |a hereditary predisposition | |
| 650 | 7 | |a TNFRSF13B protein, human |2 NLM | |
| 650 | 7 | |a Transmembrane Activator and CAML Interactor Protein |2 NLM | |
| 700 | 1 | |a Orsini, Paola |e verfasserin |4 aut | |
| 700 | 1 | |a Tarantini, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Anelli, Luisa |e verfasserin |4 aut | |
| 700 | 1 | |a Zagaria, Antonella |e verfasserin |4 aut | |
| 700 | 1 | |a Tragni, Vincenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Coccaro, Nicoletta |e verfasserin |4 aut | |
| 700 | 1 | |a Tota, Giuseppina |e verfasserin |4 aut | |
| 700 | 1 | |a Parciante, Elisa |e verfasserin |4 aut | |
| 700 | 1 | |a Conserva, Maria Rosa |e verfasserin |4 aut | |
| 700 | 1 | |a Redavid, Immacolata |e verfasserin |4 aut | |
| 700 | 1 | |a Minervini, Crescenzio Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Minervini, Angela |e verfasserin |4 aut | |
| 700 | 1 | |a Attolico, Immacolata |e verfasserin |4 aut | |
| 700 | 1 | |a Gentile, Mattia |e verfasserin |4 aut | |
| 700 | 1 | |a Pierri, Ciro Leonardo |e verfasserin |4 aut | |
| 700 | 1 | |a Specchia, Giorgina |e verfasserin |4 aut | |
| 700 | 1 | |a Musto, Pellegrino |e verfasserin |4 aut | |
| 700 | 1 | |a Albano, Francesco |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Hematological oncology |d 1993 |g 41(2023), 5 vom: 21. Dez., Seite 942-946 |w (DE-627)NLM012648280 |x 1099-1069 |7 nnns |
| 773 | 1 | 8 | |g volume:41 |g year:2023 |g number:5 |g day:21 |g month:12 |g pages:942-946 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/hon.3212 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 41 |j 2023 |e 5 |b 21 |c 12 |h 942-946 | ||